ARKD yields 331.30% · ABBV yields 3.12%● Live data
📍 ARKD pulled ahead of the other in Year 1
Combined, ARKD + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ARKD + ABBV for your $10,000?
ARKD is an actively managed ETF aiming to provide a more tampered price return for shares of ARK Innovation ETF (ticker: ARKK), over a one-year period starting each January. The fund aims to cut the downside risk in half in exchange for a capped upside potential after a 5% performance hurdle is reached. ARKK holds US and foreign equities focused on disruptive innovation themes such as genomics, AI, robotics, fintech. The fund holds shares of ARKK, sells at-the-money calls against the shares, buys at-the-money puts covering 50% of the funds NAV, and buys out-of-the-money calls with any available premium in order to provide upside exposure above the 5% hurdle. All returns are before fees and expenses, which reduce overall fund returns. ARKD shareholders do not receive dividends, if any, from shares of ARKK. The strategy works best for investors willing to hold shares the entire outcome period. Outcomes will differ for those buying/selling mid-period.
Full ARKD Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.